| Schedule of segment reporting |
| Schedule of segment reporting | |
| |
| |
| |
| |
|
| For the six months ended June 30, 2026 | |
Unallocated | |
| |
| |
| |
|
| | |
Corporate | |
| |
ADIA | |
ADIA | |
|
| | |
Overhead | |
Biolete | |
Med | |
Labs | |
Totals |
| Segment Revenue | |
| | | |
| | | |
| | | |
| | | |
| | |
| Medical procedures | |
$ | – | | |
$ | – | | |
$ | 434,670 | | |
$ | – | | |
$ | 434,670 | |
| Sales of biologics, net of discounts and refunds | |
| – | | |
| – | | |
| – | | |
| 221,525 | | |
| 221,525 | |
| Shipping and delivery | |
| – | | |
| – | | |
| – | | |
| 5,465 | | |
| 5,465 | |
| Total Segment Revenue | |
| – | | |
| – | | |
| 434,670 | | |
| 226,990 | | |
| 661,660 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Cost of Revenue | |
| | | |
| | | |
| | | |
| | | |
| | |
| Cost of goods sold | |
| – | | |
| – | | |
| 153,550 | | |
| 157,953 | | |
| 311,503 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Gross Profit | |
| – | | |
| – | | |
| 281,120 | | |
| 69,037 | | |
| 350,157 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Operating Expenses | |
| | | |
| | | |
| | | |
| | | |
| | |
| General and administrative | |
| 231,318 | | |
| – | | |
| 137,141 | | |
| 22,346 | | |
| 390,805 | |
| Advertising and promotion | |
| 1,126 | | |
| – | | |
| 58,317 | | |
| – | | |
| 59,443 | |
| Segment Operating Expenses | |
| 232,444 | | |
| – | | |
| 195,458 | | |
| 22,346 | | |
| 450,248 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Segment Profit (Loss) | |
$ | (232,444 | ) | |
$ | – | | |
$ | 85,662 | | |
$ | 46,691 | | |
$ | (100,091 | ) |
The Company chooses to disclose the following
in its segment reporting requirements for the six months ended June 30, 2025:
| | |
| |
| |
| |
| |
|
| For the six months ended June 30, 2025 | |
Unallocated | |
| |
| |
| |
|
| | |
Corporate | |
| |
ADIA | |
ADIA | |
|
| | |
Overhead | |
Biolete | |
Med | |
Labs | |
Totals |
| Segment Revenue | |
| | | |
| | | |
| | | |
| | | |
| | |
| Medical procedures | |
$ | – | | |
$ | – | | |
$ | 96,700 | | |
$ | – | | |
$ | 96,700 | |
| Sales of biologics, net of discounts and refunds | |
| – | | |
| – | | |
| – | | |
| 87,500 | | |
| 87,500 | |
| Sales of supplements | |
| – | | |
| 2,155 | | |
| – | | |
| – | | |
| 2,155 | |
| Services | |
| 2,267 | | |
| – | | |
| – | | |
| 1,288 | | |
| 3,555 | |
| Total Segment Revenue | |
| 2,267 | | |
| 2,155 | | |
| 96,700 | | |
| 88,788 | | |
| 189,910 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Cost of Revenue | |
| | | |
| | | |
| | | |
| | | |
| | |
| Cost of goods sold | |
| – | | |
| 663 | | |
| 70,788 | | |
| 78,484 | | |
| 149,935 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Gross Profit | |
| 2,267 | | |
| 1,492 | | |
| 25,912 | | |
| 10,304 | | |
| 39,975 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Operating Expenses | |
| | | |
| | | |
| | | |
| | | |
| | |
| General and administrative | |
| 146,094 | | |
| 368 | | |
| 89,151 | | |
| 307 | | |
| 235,920 | |
| Advertising and promotion | |
| 24,617 | | |
| 67 | | |
| 6,484 | | |
| 17 | | |
| 31,185 | |
| Segment Operating Expenses | |
| 170,711 | | |
| 435 | | |
| 95,635 | | |
| 324 | | |
| 267,105 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Segment Profit (Loss) | |
$ | (168,444 | ) | |
$ | 1,057 | | |
$ | (69,723 | ) | |
$ | 9,980 | | |
$ | (227,130 | ) |
|